Quarterly report pursuant to Section 13 or 15(d)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.10.0.1
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Net loss $ 3,185,910 $ (992,188) $ 3,805,244 $ (4,776,963)  
Cash flows from operations     5,369,312 204,279  
Asset impairment charges     0 0  
Cash equivalents 0   0   $ 0
Restricted cash 778,579   778,579   778,579
Cash in excess of FDIC limits 6,410,526   6,410,526    
Allowance for doubtful accounts 200,000   200,000   200,000
Shipping and handling charged to customers 487,939 166,643 806,963 324,002  
Allowance for customer returns 0   0   0
Inventory, noncurrent 3,631,346   3,631,346   5,667,101
Depreciation expense 117,014 39,322 227,210 86,847  
Research and development 442,004 205,647 595,708 394,363  
Advertising expense 220,915 108,555 402,559 175,455  
Unrecognized tax benefits 0   0   $ 0
Consumer Products [Member]          
Research and development 75,833 55,956 192,467 104,989  
Specialty Pharmaceuticals [Member]          
Research and development 366,171 $ 149,691 $ 403,241 $ 289,374  
OptionsMember          
Antidilutive shares outstanding     19,707,917    
Warrants [Member]          
Antidilutive shares outstanding     2,335,289    
Performance based stock options [Member]          
Stock that may be required to issue     10,750,000    
Germany and The Netherlands [Member]          
Inventory, noncurrent $ 680,515   $ 680,515